Directory Calendar Careers Alumni Giving

Dr. Greg Yothers, PhD

Research Associate Professor, Biostatistics

Director, NRG Oncology SDMC, Division of Biostatistics and Science, Pittsburgh

Contact

201 N Craig St, Suite 350, NRG Oncology SDMC
R-znvy: tnlfg8@cvgg.rqh
Primary Phone: 967-838-7003
Fax: 967-838-6832
Web site:


Personal Statement

My primary research interest is the design, implementation and analysis of phase II and III clinical trials for cancer research.  My work with the NRG Oncology clinical trials cooperative group has included trials evaluating therapies for the treatment of colon and rectal cancer.  The focus of my methodological research has been the development of statistical methodologies for identifying a subset of a clinical trial or population where a treatment is effective. 

 

I am the Director of the Division of Biostatistics and Science for the Pittsburgh office of the NRG Oncology Statistics and Data Management Center - leadership role in maintaining effective operations to support numerous clinical trials in a research group comprising 200 employees.  I have sole responsibility for the program of research in colorectal cancer as well as increasing responsibilities in the breast and prostate cancer disease sites. 


Education

2003 | University of Pittsburgh, Pittsburgh, PA | Doctor of Philosophy in Statistics

1998 | University of Pittsburgh, Pittsburgh, PA | Master of Arts in Statistics
1981 | Pennsylvania State University, State College, PA | Bachelor of Science in Mathematics


Selected Publications

Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O’Connell, MJ, Wolmark N, Paik S. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncology. 2016 Jun 6. PMID: 27270348. doi: 10.1001/jamaoncol.2016.2314.

 

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O’Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology. 2016 Apr 10; 34 (11):1182-9. PMID: 26858337. doi: 10.1200/JCO.2015.65.1158. 

 

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology. 2016 Mar 10; 34 (8):843-53. PMCID: PMC4872008. PMID: 26811529. doi: 10.1200/JCO.2015.63.0558.

 

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. The New England Journal of Medicine. 2016 Jan 21; 374 (3):211-22. PMCID: PMC4784450. PMID: 26789870. doi: 10.1056/NEJMoa1506597. 

 

Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Journal of The National Cancer Institute. 2015 Nov; 107 (11):1-8. PMID: 26374429. doi: 10.1093/jnci/djv248.

 

George TJ Jr, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Current Colorectal Cancer Reports. 2015 Aug 9; 11 (5):275-280. PMCID: PMC4550644. PMID: 26321890. doi: 10.1007/s11888-015-0285-2.


Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. Journal of Clinical Oncology. 2013 Dec 20; 31 (36):4512-9.  

 

Link to Greg Yothers complete bibliography...

Greg  Yothers
© 2017 by University of Pittsburgh Graduate School of Public Health

Login  |  Sitemap